IP Library › Granted Patent US 12,582,668
Granted Patent B2
US 12,582,668 · App. 17/616,292 · Granted Mar 24, 2026

Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)

Inventors: Bruce Given (Charleston, SC); Dawn Christianson (Solana Beach, CA); James C. Hamilton (Arcadia, CA); Zhen Li (San Diego, CA); Rui Zhu (San Diego, CA); Christine I. Wooddell (Madison, WI); Tao Pei (Middleton, WI)
Assignee: Arrowhead Pharmaceuticals, Inc.
A61K31/713A61K45/06A61P1/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,668
App. No.
17/616,292
Granted
Mar 24, 2026
Kind
B2
Abstract

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

Claims (46)

1 . A method of treating alpha-1 antitrypsin deficiency (AATD) in a human subject in need thereof, the method comprising administering by subcutaneous injection to the subject doses of a pharmaceutical composition comprising about 5 mg to about 300 mg of an AAT RNAi Drug Substance, wherein the AAT RNAi Drug Substance comprises:

a sense strand comprising the structure of (NAG37) s (invAb) sagcguuuaGfGfCfauguuuaacas (invAb) (SEQ ID NO:6) and an antisense strand comprising the structure of usGfsuUfaAfacaugCfcUfaAfaCfgCfsu (SEQ ID NO:2), wherein the sense and antisense strands are annealed to form a duplex,

wherein a, c, g, and u represent 2′-O-methyl adenosine, 2′-O-methyl cytidine, 2′-O-methyl guanosine, and 2′-O-methyl uridine, respectively; Af, Cf, Gf, and Uf represent 2′-fluoro adenosine, 2′-fluoro cytidine, 2′-fluoro guanosine, and 2′-fluoro uridine, respectively; s represents a phosphorothioate linkage; (invAb) represents an inverted abasic deoxyribose residue; and

(NAG37) s represents the structure of

or both,

wherein the pharmaceutical composition is administered once every 28 days.

2 . A method of treating alpha-1 antitrypsin deficiency (AATD) in a human subject in need thereof, the method comprising administering by subcutaneous injection to the subject doses of a pharmaceutical composition comprising about 5 mg to about 300 mg of an AAT RNAi Drug Substance, wherein the AAT RNAi Drug Substance comprises:

a sense strand comprising the structure of (NAG37) s (invAb) sagcguuuaGfGfCfauguuuaacas (invAb) (SEQ ID NO:6) and an antisense strand comprising the structure of usGfsuUfaAfacaugCfcUfaAfaCfgCfsu (SEQ ID NO:2), wherein the sense and antisense strands are annealed to form a duplex,

wherein a, c, g, and u represent 2′-O-methyl adenosine, 2′-O-methyl cytidine, 2′-O-methyl guanosine, and 2′-O-methyl uridine, respectively; Af, Cf, Gf, and Uf represent 2′-fluoro adenosine, 2′-fluoro cytidine, 2′-fluoro guanosine, and 2′-fluoro uridine, respectively; s represents a phosphorothioate linkage; (invAb) represents an inverted abasic deoxyribose residue; and

(NAG37) s represents the structure of

or both,

wherein the pharmaceutical composition is administered once every 84 days.

3 . A method of treating alpha-1 antitrypsin deficiency (AATD) in a human subject in need thereof, the method comprising administering to the subject by subcutaneous administration doses of a pharmaceutical composition comprising about 5 mg to about 300 mg of an AAT RNAi Drug Substance, wherein the AAT RNAi Drug Substance comprises:

a sense strand comprising the structure of (NAG37) s (invAb) sagcguuuaGfGfCfauguuuaacas (invAb) (SEQ ID NO:6) and an antisense strand comprising the structure of usGfsuUfaAfacaugCfcUfaAfaCfgCfsu (SEQ ID NO:2), wherein the sense and antisense strands are annealed to form a duplex,

wherein a, c, g, and u represent 2′-O-methyl adenosine, 2′-O-methyl cytidine, 2′-O-methyl guanosine, and 2′-O-methyl uridine, respectively; Af, Cf, Gf, and Uf represent 2′-fluoro adenosine, 2′-fluoro cytidine, 2′-fluoro guanosine, and 2′-fluoro uridine, respectively; s represents a phosphorothioate linkage; (invAb) represents an inverted abasic deoxyribose residue; and

(NAG37) s represents the structure of

or both,

wherein the administration comprises:

a. administering to the subject an initial dose of the pharmaceutical composition,

b. administering to the subject a second dose of the pharmaceutical composition about 28 days after the initial dose, and

c. administering to the subject a third dose of the pharmaceutical composition about 84 days after the second dose.

4 . The method of claim 3 , wherein each dose of the pharmaceutical composition comprises the AAT RNAi Drug Substance in an amount of about 25 mg to about 300 mg.

5 . The method of claim 3 , wherein each dose of the pharmaceutical composition comprises the AAT RNAi Drug Substance in an amount of about 100 mg to about 200 mg.

6 . The method of claim 3 , wherein each dose of the pharmaceutical composition comprises the AAT RNAi Drug Substance in an amount of about 25 mg.

7 . The method of claim 3 , wherein each dose of the pharmaceutical composition comprises the AAT RNAi Drug Substance in an amount of about 35 mg.

8 . The method of claim 3 , wherein each dose of the pharmaceutical composition comprises the AAT RNAi Drug Substance in an amount of about 100 mg.

9 . The method of claim 3 , wherein each dose of the pharmaceutical composition comprises the AAT RNAi Drug Substance in an amount of about 200 mg.

10 . The method of claim 3 , wherein each dose of the pharmaceutical composition comprises the AAT RNAi Drug Substance in an amount of about 180 mg to about 240 mg.

11 . The method of claim 3 , wherein the condition or disease caused by AATD is a liver disease.

12 . The method of claim 11 , wherein the liver disease is chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, or fulminant hepatic failure.

13 . The method of claim 3 , wherein the subject is further administered an additional therapeutic for the treatment of AATD.

14 . The method of claim 3 , wherein the subject is further administered a therapeutic for the treatment of lung damage, emphysema, or other lung diseases or disorders caused by the deficiency of endogenously secreted AAT protein.

15 . The method of claim 14 , wherein the additional therapeutic comprises human AAT protein, purified human alpha-1 proteinase inhibitor, or recombinant AAT protein.

16 . The method of claim 3 , wherein the pharmaceutical composition is packaged in a kit, container, pack, dispenser, pre-filled syringe, or vials.

17 . The method of claim 3 , wherein the pharmaceutical composition comprises, consists of, or consists essentially of the Formulated AAT RNAi Drug Substance comprising the AAT RNAi Drug Substance formulated at 230 mg/mL in an aqueous sodium phosphate buffer of 0.5 mM sodium phosphate monobasic and 0.5 mM sodium phosphate dibasic.

18 . The method of claim 3 , further comprising administering additional doses after the third dose, wherein the additional doses are administered about 84 days apart.

19 . The method of claim 3 , wherein the administration of one or more doses of the pharmaceutical composition is performed by the subject.

20 . The method of claim 3 , wherein the administration of one or more doses of the pharmaceutical composition is performed by a medical professional.

21 . A method of treating alpha-1 antitrypsin deficiency (AATD) in a human subject in need thereof, the method comprising administering to the subject by subcutaneous administration doses of a pharmaceutical composition comprising about 200 mg of an AAT RNAi Drug Substance, wherein the AAT RNAi Drug Substance comprises:

a sense strand comprising the structure of (NAG37) s (invAb) sagcguuuaGfGfCfauguuuaacas (invAb) (SEQ ID NO:6) and an antisense strand comprising the structure of usGfsuUfaAfacaugCfcUfaAfaCfgCfsu (SEQ ID NO:2), wherein the sense and antisense strands are annealed to form a duplex, wherein a, c, g, and u represent 2′-O-methyl adenosine, 2′-O-methyl cytidine, 2′-O-methyl guanosine, and 2′-O-methyl uridine, respectively; Af, Cf, Gf, and Uf represent 2′-fluoro adenosine, 2′-fluoro cytidine, 2′-fluoro guanosine, and 2′-fluoro uridine, respectively; s represents a phosphorothioate linkage; (invAb) represents an inverted abasic deoxyribose residue; and (NAG37) s represents the structure of

or both,

wherein the administration comprises:

a. administering to the subject an initial dose of the pharmaceutical composition,

b. administering to the subject a second dose of the pharmaceutical composition comprising about 28 days after the initial dose, and

c. administering to the subject a third dose of the pharmaceutical composition comprising about 84 days after the second dose.

22 . The method of claim 21 , further comprising administering additional doses after the third dose, wherein the additional doses are administered about 84 days apart.

Assignments (2)
SECURITY INTEREST Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2022
From: GIVEN, BRUCE; CHRISTIANSON, DAWN; HAMILTON, JAMES C.; ZHU, RUI; LI, ZHEN; WOODDELL, CHRISTINE I.; PEI, TAO
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 060157/0375 →
Continuity (2)
Provisional Application 62858059 · Jun 6, 2019
Related Publication 20220305046A1 · Sep 29, 2022
References Cited (182)
US 3687808A · Merigan et al. · 1972 [cited by applicant]
US 5034506A · Summerton et al. · 1991 [cited by applicant]
US 5134066A · Rogers et al. · 1992 [cited by applicant]
US 5212295A · Cook · 1993 [cited by applicant]
US 5359044A · Cook et al. · 1994 [cited by applicant]
US 5459255A · Cook et al. · 1995 [cited by applicant]
US 5466786A · Buhr et al. · 1995 [cited by applicant]
US 5489677A · Sanghvi et al. · 1996 [cited by applicant]
US 5519134A · Acevedo et al. · 1996 [cited by applicant]
US 5521302A · Cook · 1996 [cited by applicant]
US 5539082A · Nielson et al. · 1996 [cited by applicant]
US 5552540A · Haralambidis · 1996 [cited by applicant]
US 5587361A · Cook et al. · 1996 [cited by applicant]
US 5591722A · Montgomery et al. · 1997 [cited by applicant]
US 5594121A · Froehler et al. · 1997 [cited by applicant]
US 5596091A · Switzer · 1997 [cited by applicant]
US 5597909A · Urdea et al. · 1997 [cited by applicant]
US 5602240A · De Mesmaeker et al. · 1997 [cited by applicant]
US 5646265A · McGee · 1997 [cited by applicant]
US 5700920A · Altmann et al. · 1997 [cited by applicant]
US 5885968A · Biessen et al. · 1999 [cited by applicant]
US 6172209B1 · Manoharan et al. · 2001 [cited by applicant]
US 6268490B1 · Imanishi et al. · 2001 [cited by applicant]
US 6271358B1 · Manoharan et al. · 2001 [cited by applicant]
US 7056704B2 · Tuschl et al. · 2006 [cited by applicant]
US 7335765B2 · Kaneko et al. · 2008 [cited by applicant]
US 7691997B2 · Khvorova et al. · 2010 [cited by applicant]
US 8084599B2 · Rossi et al. · 2011 [cited by applicant]
US 8349809B2 · Brown · 2013 [cited by applicant]
US 8394628B2 · Tuschl et al. · 2013 [cited by applicant]
US 8513207B2 · Brown · 2013 [cited by applicant]
US 8648185B2 · Mcswigen et al. · 2014 [cited by applicant]
US 9340784B2 · Monia et al. · 2016 [cited by applicant]
US 9458457B2 · Brown et al. · 2016 [cited by applicant]
US 9879261B2 · Brown et al. · 2018 [cited by applicant]
US 10006025B2 · Wooddell et al. · 2018 [cited by applicant]
US 10450565B2 · Li · 2019 [cited by examiner]
US 11203756B2 · Li · 2021 [cited by examiner]
US 11384355B2 · Wooddell et al. · 2022 [cited by applicant]
US 11884920B2 · Li et al. · 2024 [cited by applicant]
US 12188017B2 · Wooddell et al. · 2025 [cited by applicant]
US 20050137153A1 · Mcswiggen et al. · 2005 [cited by applicant]
US 20060234247A1 · Puttaraju et al. · 2006 [cited by applicant]
US 20070253936A1 · Kay et al. · 2007 [cited by applicant]
US 20090029931A1 · Tachas et al. · 2009 [cited by applicant]
US 20090247608A1 · Manoharan et al. · 2009 [cited by applicant]
US 20100048680A1 · Liu et al. · 2010 [cited by applicant]
US 20100056768A1 · Wengel · 2010 [cited by applicant]
US 20110028531A1 · Feinstein et al. · 2011 [cited by applicant]
US 20110207799A1 · Rozema et al. · 2011 [cited by applicant]
US 20130190484A1 · Rozema et al. · 2013 [cited by applicant]
US 20130281658A1 · Rozema et al. · 2013 [cited by applicant]
US 20140235693A1 · Sehgal et al. · 2014 [cited by applicant]
US 20140350071A1 · Sehgal et al. · 2014 [cited by applicant]
US 20150011607A1 · Brown et al. · 2015 [cited by applicant]
US 20150361427A1 · Wooddell et al. · 2015 [cited by applicant]
US 20160244752A1 · Sehgal et al. · 2016 [cited by applicant]
US 20170035796A1 · Wooddell et al. · 2017 [cited by applicant]
US 20170130221A1 · Brown et al. · 2017 [cited by applicant]
US 20170253875A1 · Rozema et al. · 2017 [cited by applicant]
US 20180064819A1 · Li et al. · 2018 [cited by applicant]
US 20180195069A1 · Li et al. · 2018 [cited by applicant]
US 20180258430A1 · Wooddell et al. · 2018 [cited by applicant]
US 20190071670A1 · Wooddell et al. · 2019 [cited by applicant]
US 20190284558A1 · Wooddell et al. · 2019 [cited by applicant]
US 20200208149A1 · Li et al. · 2020 [cited by applicant]
US 20220170015A1 · Li et al. · 2022 [cited by applicant]
US 20230002768A1 · Wooddell et al. · 2023 [cited by applicant]
US 20230348905A1 · Christianson et al. · 2023 [cited by applicant]
US 20240141351A1 · Li et al. · 2024 [cited by applicant]
US 20250197861A1 · Wooddell et al. · 2025 [cited by applicant]
CN 103547272A · 2014 [cited by applicant]
CN 106535917A · 2017 [cited by applicant]
JP 2008516991A · 2008 [cited by applicant]
JP 2013539967A · 2013 [cited by applicant]
JP 2016520312A · 2016 [cited by applicant]
JP 2020503070A · 2020 [cited by applicant]
WO WO1993007883A1 · 1993 [cited by applicant]
WO WO1997044348A1 · 1997 [cited by applicant]
WO WO1999014226A2 · 1999 [cited by applicant]
WO WO1999038987A1 · 1999 [cited by applicant]
WO WO2000053722A2 · 2000 [cited by applicant]
WO WO2004045543A2 · 2004 [cited by applicant]
WO WO2004083430A1 · 2004 [cited by applicant]
WO WO2006086821A1 · 2006 [cited by applicant]
WO WO2008016391A2 · 2008 [cited by applicant]
WO WO2008022309A2 · 2008 [cited by applicant]
WO WO2011104169A1 · 2011 [cited by applicant]
WO WO2012033848A1 · 2012 [cited by applicant]
WO WO2012083185A2 · 2012 [cited by applicant]
WO WO2012178033A2 · 2012 [cited by applicant]
WO WO2013032829A1 · 2013 [cited by applicant]
WO WO2013142514A1 · 2013 [cited by applicant]
WO WO2013158141A1 · 2013 [cited by applicant]
WO WO2014190137A1 · 2014 [cited by applicant]
WO WO2014197524A2 · 2014 [cited by applicant]
WO WO2015003113A2 · 2015 [cited by applicant]
WO WO2015188197A2 · 2015 [cited by applicant]
WO WO2015195628A2 · 2015 [cited by applicant]
WO WO2017139616A1 · 2017 [cited by applicant]
WO WO2017156012A1 · 2017 [cited by applicant]
WO WO2017214518A1 · 2017 [cited by applicant]
WO WO2018098117A1 · 2018 [cited by applicant]
WO WO2018132432A1 · 2018 [cited by applicant]
WO WO2018236273A1 · 2018 [cited by applicant]
WO WO2020247774A1 · 2020 [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/036359 mailed Sep. 30, 2020. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2020/036359 mailed Dec. 16, 2021. [cited by applicant]
Akinc et al., Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. Jul. 2010;18(7):1357-64. doi: 10.1038/mt.2010.85. Epub May 11, 2010. [cited by applicant]
American Thoracic Society, American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. Oct.… [cited by applicant]
Baenziger et al., Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes. Cell. Nov. 1980;22(2 Pt 2):611-20. doi: 10.1016/0092-8674(80)90371-2. [cited by applicant]
Bals, Alpha-1-antitrypsin deficiency. Best Pract Res Clin Gastroenterol. Oct. 2010;24(5):629-33. doi: 10.1016/j.bpg.2010.08.006. [cited by applicant]
Biessen et al., Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor. J Med Chem. Apr. 28, 1995;38(9):1538-46. doi: 10.1021/jm00009a014. [cited by applicant]
Bondensgaard et al., Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity. Chemistry. Aug. 4, 2000;6(15):2687-95. doi: 10.1002/1521-3765(20000804)6:15<2687::aid-chem2687>3.0… [cited by applicant]
Braasch et al., Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol. Jan. 2001;8(1):1-7. doi: 10.1016/s1074-5521(00)00058-2. [cited by applicant]
Carlson et al., Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest. Apr. 1989;83(4):1183-90. doi: 10.1172/JCI113999. [cited by applicant]
Carrell et al., Alpha1-antitrypsin deficiency—a model for conformational diseases. N Engl J Med. Jan. 3, 2002;346(1):45-53. doi: 10.1056/NEJMra010772. [cited by applicant]
Cichy et al., Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem. Mar. 28, 1997;272(13):8250-5. doi: 10.1074/jbc.272.13.8250. [cited by applicant]
Cohen, Interrelationships between the human alveolar macrophage and alpha-1-antitrypsin. J Clin Invest. Nov. 1973;52(11):2793-9. doi: 10.1172/JCI107475. [cited by applicant]
Connolly et al., Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation. J Biol Chem. Jan. 25, 1982;257(2):939-45. [cited by applicant]
Cook, Medicinal Chemistry of Antisense Oligonucleotides-Future Opportunities. Anti-Cancer Drug Des. Dec. 1991;6(6):585-607. [cited by applicant]
Crinelli et al., Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res. Jun. 1, 2002;30(11):2435-43. doi: 10.1093/nar/30.11.2435. [cited by applicant]
Crooke et al., Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther. May 1996;277(2):923-37. [cited by applicant]
Cruz et al., In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest. Sep. 2007;87(9):893-902. doi: 10.1038/labinvest.3700629. Epub Jun. 25, 2007. [cited by applicant]
Cruz et al., Post-Transcriptional Gene Silencing of Alpha-I Antitrypsin by Small Interfering RNAs (siRNA). Mol Ther. 2006; 13(1):S45-S46. [cited by applicant]
Czauderna et al., Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. Jun. 1, 2003;31(11):2705-16. doi: 10.1093/nar/gkg393. [cited by applicant]
De Serres et al., Prevalence of al-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Th… [cited by applicant]
Delgado et al., The Uses and Properties of PEG-Linked Proteins. Crit Rev Ther Drug Carrier Syst. 1992;9(3-4):249-304. [cited by applicant]
Elmen et al., Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. Jan. 14, 2005;33(1):439-47. doi: 10.1093/nar/gki193. Print 2005. [cited by applicant]
Elzouki et al., Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Ga… [cited by applicant]
Eriksson, Alpha-1-antitrypsin deficiency: natural course and therapeutic strategies. Falk Symposium 115: Liver cirrhosis and its development. 2001; 307-15. [cited by applicant]
Feldmann et al., The ultrastructure of hepatocytes in alpha-1-antitrypsin deficiency with the genotype Pi--. Gut. Oct. 1975;16(10):796-9. doi: 10.1136/gut.16.10.796. [cited by applicant]
Flotte et al., Gene therapy for alpha-1 antitrypsin deficiency. Hum Mol Genet. Apr. 15, 2011;20(R1):R87-92. doi: 10.1093/hmg/ddr156. Epub Apr. 16, 2011. [cited by applicant]
Greene et al., Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J Gastrointest Pharmacol Ther. Oct. 6, 2010;1(5):94-101. doi: 10.4292/wjgpt.v1.i5.94. [cited by applicant]
Grimm et al., Fatality in mice due to oversaturation of cellular microRNA/short haiipin RNA Pathways. Nature. May 25, 2006;441(7092):537-41. doi: 10.1038/nature04791. [cited by applicant]
Guo et al., Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. J Clin Invest. Jan. 2014;124(1):251-61. doi: 10.1172/JCI67968. Epub Dec. 20, 2013. [cited by applicant]
Guzaev et al., A conformationally preorganized universal solid support for efficient oligonucleotide synthesis. J Am Chem Soc. Mar. 5, 2003;125(9):2380-1. doi: 10.1021/ja0284613. [cited by applicant]
Hamm et al., Incorporation of 2′-Deoxy-2′-mercaptocytidine into Oligonucleotides via Phosphoramidite Chemistry. J Org Chem. May 16, 1997;62(10):3415-3420. doi: 10.1021/jo9700960. [cited by applicant]
Hunt et al., Alpha 1 anti-trypsin: one protein, many functions. Curr Mol Med. Aug. 2012;12(7):827-35. doi: 10.2174/156652412801318755. [cited by applicant]
Iobst et al., Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors. J Biol Chem. Mar. 22, 1996;271(12):6686-93. doi: 10.1074/jbc.271.12.6686. [cited by applicant]
Joshi et al., siRNA: novel therapeutics from functional genomics. Biotechnol Genet Eng Rev. Oct. 2014;30(1-2):1-30. doi: 10.1080/02648725.2014.921495. [cited by applicant]
Kabanov et al., A new class of antivirals; antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells. FEBS… [cited by applicant]
Kamola et al., The siRNA Non-seed Region and Its Target Sequences are Auxiliary Determinants of Off-Target Effects. PLoS Comput Biol. Dec. 11, 2015;11(12):e1004656. doi: 10.1371/journal.pcbi.1004656. eCollection Dec. 20… [cited by applicant]
Kemmer et al., Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc. Jun. 2008;40(5):1492-4. doi: 10.1016/j.transproceed.2008.02.075. [cited by applicant]
Kok et al., Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. BMC Gastroenterology. Feb. 20, 2010;10:22. doi: 10.1186/1… [cited by applicant]
Kurreck et al., Design of Antisense Oligonucleotides Stabilized by Locked Nucleic Acids. Nucleic Acids Res. May 1, 2002;30(9):1911-8. doi: 10.1093/nar/30.9.1911. [cited by applicant]
Letsinger et al., Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci USA. Sep. 1989;86(17):6553-… [cited by applicant]
Li et al., Combination Therapy Utilizing shRNA and Optimize Alpha-I Antitrypsin (AAT) Expression Cassette for Treatment and Correction of AAT Liver Deficiency. Mol Ther. 2009; 17(1):S12. [cited by applicant]
Lindblad et al., Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. Hepatology. Oct. 2007;46(4):1228-35. doi: 10.1002/hep.21822. [cited by applicant]
Lomas et al., The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. Jun. 18, 1992;357(6379):605-7. doi: 10.1038/357605a0. [cited by applicant]
Long et al., Complete sequence of the cDNA for human alpha 1-antitrypsin and the gene for the S variant. Biochemistry. Oct. 9, 1984;23(21):4828-37. doi: 10.1021/bi00316a003. [cited by applicant]
Manoharan et al., Lipidic Nucleic Acids. Tetrahedron Letters. 1995; 36: 3651-4. [cited by applicant]
McLean et al., Gene targeted therapeutics for liver disease in alpha-I antitrypsin deficiency. Biologics. 2009;3:63-75. Epub Jul. 13, 2009. [cited by applicant]
Mishra et al., Improved leishmanicidal effect of phosphorothioate antisense oligonucleotides by LDL-mediated delivery. Biochim Biophys Acta. Nov. 7, 1995;1264(2):229-37. doi: 10.1016/0167-4781(95)00145-7. [cited by applicant]
Mueller et al., Development of Simultaneous Gene Augmentation and Reduction of Mutant Gene Expression with a Single Recombinant AA V for Alpha One Antitrypsin Disease. Mol Ther. 2009; 17(1): S391-S392. [cited by applicant]
Mueller et al., In Vivo Allele Specific Knockdown of Mutant Alpha One Antitrypsin using Recombinant AA V Delivered shRNA. Mol Ther. 2009; 17(1): S313. [cited by applicant]
Mueller et al., Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther. Mar. 2012;20(3):590-600. doi: 10.1038/mt.2011… [cited by applicant]
Nelson et al., Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol. Jun. 2012;10(6):575-80. doi: 10.1016/j.cgh.2011.12.028. Epub Dec. 23, 2011. [cited by applicant]
Nielsen et al., Incorporation of (R)- and (S)-3′,4′-seco-thymidine into oligodeoxynucleotides: hybridization properties and enzymatic stability. Nucleic Acids Res. Mar. 11, 1994;22(5):703-10. doi: 10.1093/nar/22.5.703. [cited by applicant]
Nielsen et al., Synthesis and evaluation of oligodeoxynucleotides containing acyclic nucleosides: introduction of three novel analogues and a summary. Bioorg Med Chem. Jan. 1995;3(1):19-28. doi: 10.1016/0968-0896(94)001… [cited by applicant]
Paakko et al., Activated neutrophils secrete stored alpha 1-antitrypsin. Am J Respir Crit Care Med. Dec. 1996;154(6 Pt 1):1829-33. doi: 10.1164/ajrccm.154.6.8970377. [cited by applicant]
Perlmutter et al., Hepatic fibrosis and carcinogenesis in α1-antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function disorders. Cold Spring Harb Perspect Biol. Mar. 1, 2011;3(3):a005801. doi: 1… [cited by applicant]
Perlmutter, Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu Rev Med. 2011;62:333-45. doi: 10.1146/annurev-me… [cited by applicant]
Propst et al., Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency. J Hepatol. Dec. 1994;21(6):1006-11. doi: 10.1016/s0168-8278(05)80609-9. [cited by applicant]
Saison-Behmoaras et al., Short Modified Antisense Oligonucleotides Directed Against Ha-ras Point Mutation Induce Selective Cleavage of the mRNA and Inhibit T24 Cells Proliferation. Embo J. May 1991;10(5):1111-8. [cited by applicant]
Sehgal et al., Developing an RNAi Therapeutic for Liver Disease Associated With Alpha-1-Antitrypsin Deficiency. AASLD Abstracts. Oct. 2013. 58(4): 412A-14. [cited by applicant]
Shea et al., Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates. Nucleic Acids Res. Jul. 11, 1990;18(13):3777-83. doi: 10.1093/nar/18.13.3777. [cited by applicant]
Song et al., Crystal structure of an uncleaved alpha 1-antitrypsin reveals the conformation of its inhibitory reactive loop. FEBS Lett. Dec. 18, 1995;377(2):150-4. doi: 10.1016/0014-5793(95)01331-8. [cited by applicant]
Stoller et al., A review of al-antitrypsin deficiency. Am J Respir Crit Care Med. Feb. 1, 2012;185(3):246-59. doi: 10.1164/rccm.201108-1428CI. Epub Sep. 29, 2011. [cited by applicant]
Sveger, Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. Jun. 10, 1976;294(24):1316-21. doi: 10.1056/NEJM197606102942404. [cited by applicant]
Svinarchuk et al., Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups. Biochimie. 1993;75(1-2):49-54. doi: 10.1016/0300-9084(93)90024-m. [cited by applicant]
Teckman et al., Advances in alpha-1-antitrypsin deficiency liver disease. Curr Gastroenterol Rep. Jan. 2014;16(1):367. doi: 10.1007/s11894-013-0367-8. [cited by applicant]
Teckman et al., Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol. May 2004;286(5):G851-62. doi: 10.1152/ajpgi.00175.2003. Epub Dec. 18, 2003. [cited by applicant]
Teckman, Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy. COPD. Mar. 2013;10 Suppl 1:35-43. doi: 10.3109/15412555.2013.765839. [cited by applicant]
Thomson et al., Synthesis and Properties of Diuridine Phosphate Analogues Containing Thio and Amino Modifications. J Org Chem. Sep. 6, 1996;61(18):6273-6281. doi: 10.1021/jo9607951. [cited by applicant]
Venembre et al., Secretion of alpha 1-antitrypsin by alveolar epithelial cells. FEBS Lett. Jun. 13, 1994;346(2-3):171-4. doi: 10.1016/0014-5793(94)80695-0. [cited by applicant]
Wagner, The state of the art in antisense research. Nat Med. Nov. 1995;1(11):1116-8. doi: 10.1038/nm1195-1116. [cited by applicant]
Wahlestedt et al., Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A. May 9, 2000;97(10):5633-8. doi: 10.1073/pnas.97.10.5633. [cited by applicant]
Extended European Search Report for Application No. 20818171.9, mailed Oct. 2, 2023. [cited by applicant]
Geary et al., Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem Pharmacol. Aug. 1, 2009;78(3):284… [cited by applicant]
Turner et al., Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. J Hepatol. Aug. 2018;69(2):378-384. doi: 10.1016/j.jhep.2018.03.012. Epub Mar. 21, … [cited by applicant]
Yamansarov et al., Low molecular weight glycoconjugates of the antiviral drug ribavirin with galactosamine derivatives—a new approach to targeted therapy of liver diseases. Russian Biotherapeutic Journal, Special Issue:… [cited by applicant]